Navigation Links
Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009
Date:4/30/2009

Conference Call Scheduled for Thursday, May 7, 2009 at 5:30 p.m. Eastern Time

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will release results for its first fiscal quarter ended March 31, 2009, on Thursday, May 7, 2009, following the close of the U.S. financial markets. The Company will host an investor conference call to discuss the financial results and other clinical development updates at 5:30 p.m. Eastern Time the same day. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PMBBFPEVC.

To access the live conference call via phone, dial 888-679-8038. International callers may access the live call by dialing 617-213-4850. The reference number to enter the call is 78345594.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 16474219.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercializatio
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Express ... Supplies Pty Ltd are pleased to announce a ... the Australian and New Zealand distributor of DrugCheck® onsite ... Supercar Team participated in the Austin 400 May 17-19 ... into an agreement that involves each car of the ...
(Date:5/22/2013)... 2013 Envera announced today that Michael ... Mr. McErlean has an extensive background in cell production ... his career. , Mike Matheny, President and ... have Mike join our team”. “Mike’s background is perfectly ... fermentation and downstream processing equipment”, added Matheny. “Mike’s ...
(Date:5/22/2013)... Canada (PRWEB) May 22, 2013 ... approaches for deciphering the information they encode. There ... ribosome profiling (deep sequencing of ribosome protected fragments) ... in vivo. , Keynote speakers include Dr. Jonathan ... Francisco and the Howard Hughes Medical Institute, who ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... new biochip technology could eliminate animal testing in the ... in the development of new pharmaceuticals, according to new ... Institute, the University of California at Berkeley, and Solidus ... will be featured in the online Early Edition of ...
... hemostasis kit combines two important surgical tools: Baxter,s ... human thrombin ... Baxter Healthcare,Corporation today announced the Food and Drug Administration ... and human,thrombin). GELFOAM Plus is the only available hemostasis ...
... (NASDAQ: ANPI , TSX: ANP), a global ... it has submitted a 510(k),application to the U.S. ... 5-Fluorouracil-coated (5-FU) Central Venous,Catheter (CVC)., "We are ... application to,the FDA for our 5-FU CVC, as ...
Cached Biology Technology:Biochip mimics the body to reveal toxicity of industrial compounds 2Biochip mimics the body to reveal toxicity of industrial compounds 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 2Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 3Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 4Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 5
(Date:5/22/2013)... endanger the whole organism, as they may lead to ... Munich now report how byproducts of respiration cause mispairing ... in our cells controls the form and function of ... this are encoded in the linear sequence of the ... cytosine (C), guanine (G) and thymine (T). Random changes ...
(Date:5/22/2013)... and wild plants have slowed in recent years, according ... University of Leeds and the Naturalis Biodiversity Centre in ... the diversity of species in Britain, Belgium and the ... picture brightened markedly after 1990, with a slowdown in ... wild plants. , Professor Bill Kunin, Professor ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... Boston University School of Medicine (BUSM) faculty members, ... and psychiatry and Michael Silverstein, MD, an associate ... National Institute of Mental Health (NIMH) Biobehavioral Research ... ten other investigators from around the country. The ...
... everyday life and are involved in leisure activities rarely ... University of Gothenburg, Sweden. Occupational therapist Christina Andersson, ... life affects alcohol consumption as part of the wider ... has been ongoing at the Sahlgrenska Academy since the ...
... system can affect healthy people,s personality traits as well ... behaviour, reveals a thesis from the University of Gothenburg, ... and is responsible for defending humans against infection as ... therefore vital for our survival. Research has demonstrated that ...
Cached Biology News:Boston University School of Medicine researchers receive NIMH brain awards 2Women involved in leisure activities drink less alcohol 2Genes of the immune system are associated with increased risk of mental illness 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... Tecan has 20 years of expertise in ... and still offers the most powerful systems ... up to 40 000 in-microplate tests requiring ... integration of different modules (such as worktable ...
... Luciferase-based ENGENISTM (Entire Gene/cDNA or Isolated ... provide a quantitative approach for evaluation of ... serve as an efficient target for RNA ... algorithms are not perfect, leaving the probability ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
Biology Products: